person · Reporting owner

STACK DAVID M

Disclosed activity across 3 companies

Tapewire entity: 112205
SEC CIK: 0001204788

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMARIN CORP PLC\UKAMRN · Entity 5970	Director	June 14, 2021	June 17, 2021
Pacira BioSciences, Inc.PCRX · Entity 4928	Director · CEO and Chairman	June 14, 2023	June 16, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMARIN CORP PLC\UK

Report date June 14, 2021 · Filed June 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2031-06-14	Direct	45,953	Reported balance After 2021-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-14 · Grant · Acquired 45,953 · Balance 45,953 F1: On June 14, 2021, the Reporting Person was granted an option to purchase 45,953 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in 2022. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	36,000	Reported balance After 2021-06-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-14 · Grant · Acquired 36,000 · Balance 36,000 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 14, 2021, the Reporting Person was granted 36,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: On June 14, 2021, the Reporting Person was granted an option to purchase 45,953 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in 2022.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.

F4: On June 14, 2021, the Reporting Person was granted 36,000 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in such year.

F5: Not applicable.

Pacira BioSciences, Inc.

Report date June 14, 2023 · Filed June 16, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	186,481	Reported balance After 2023-06-14 transaction · row 1 1 source row Row 1 · 2023-06-14 · Grant · Acquired 32,700 · Balance 186,481 F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.74 · Expires 2033-06-14	Direct	245,400	Reported balance After 2023-06-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-06-14 · Grant · Acquired 245,400 · Balance 245,400 F3: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Common StockSEC Table I · non-derivative	IndirectBy Three Colleens Investment, LLC	97,273	Reported balance Holding disclosure · report date 2023-06-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 97,273 F2: Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
Common StockSEC Table I · non-derivative	IndirectBy Stack Schroon Mohawk FLP	18,596	Reported balance Holding disclosure · report date 2023-06-14 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 18,596 F2: Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
Common StockSEC Table I · non-derivative	IndirectLCK Investment LLC	315	Reported balance Holding disclosure · report date 2023-06-14 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 315 F2: Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.

F3: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHIASMA, INC

Report date August 05, 2021 · Filed August 05, 2021

Section 16 reporting ended · disclosed 2021-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2021-08-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2021-08-05 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F2: At the Effective Time, each share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five ordinary shares of Parent. F3: Shares held by Three Colleens Investment LLC, a limited liability company jointly owned and managed by the Reporting Person and his spouse. This Form 4 shall not be deemed an admission of beneficial ownership of these shares by the Reporting Person except to the extent of his pecuniary interest therein.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29	Direct	Reported balance After 2021-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-08-05 · Disposition to issuer · Disposed 91,954 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.57	Direct	Reported balance After 2021-08-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-08-05 · Disposition to issuer · Disposed 72,683 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14	Direct	Reported balance After 2021-08-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-08-05 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35	Direct	Reported balance After 2021-08-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45	Direct	Reported balance After 2021-08-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.98	Direct	Reported balance After 2021-08-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81	Direct	Reported balance After 2021-08-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-08-05 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time"). F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of May 4, 2021, by and among Chiasma, Inc. (the "Company), Amryt Pharma plc ("Parent"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub") pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the "Effective Time").

F2: At the Effective Time, each share of common stock of the Company (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.396 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing five ordinary shares of Parent.

F3: Shares held by Three Colleens Investment LLC, a limited liability company jointly owned and managed by the Reporting Person and his spouse. This Form 4 shall not be deemed an admission of beneficial ownership of these shares by the Reporting Person except to the extent of his pecuniary interest therein.

F4: At the Effective Time, each option to purchase Shares (each, a "Company Option") that was outstanding and unexercised prior to the Effective Time, whether or not vested, by virtue of the Merger, ceased to represent a right to acquire Shares and was converted into the option to purchase Parent ADSs (each an "Assumed Stock Option"). The number of Parent ADSs shall be equal to (i) number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 18, 2019 Filed Sep 20, 2019 17:13 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	7,500	$1.61	$12,075.00	Disclosure SEC source: 0001209191-19-050359 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 15, 2019 Filed Aug 16, 2019 16:19 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	12,849	$0.00 Strike: $10.81	$0.00	Disclosure SEC source: 0001209191-19-046315 · doc4.xml · derivative · entry 6 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,849 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document
August 15, 2019 Filed Aug 16, 2019 16:19 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	2,391	$39.61	$94,707.51	Disclosure SEC source: 0001209191-19-046315 · doc4.xml · nonDerivative · entry 3 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,299 F1 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.54 to $39.69, inclusive. Read SEC document
August 15, 2019 Filed Aug 16, 2019 16:19 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	10,458	$39.05	$408,384.90	Disclosure SEC source: 0001209191-19-046315 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,690 F1 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.54 to $39.53, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document
August 15, 2019 Filed Aug 16, 2019 16:19 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	12,849	$10.81	$138,897.69	Disclosure SEC source: 0001209191-19-046315 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document
July 11, 2019 Filed Jul 13, 2019 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	28,847	$0.00 Strike: $2.19	$0.00	Disclosure SEC source: 0001209191-19-042001 · doc4.xml · derivative · entry 5 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 28,847 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. Read SEC document
July 11, 2019 Filed Jul 13, 2019 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	23,144	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-042001 · doc4.xml · derivative · entry 4 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 23,144 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. Read SEC document
July 11, 2019 Filed Jul 13, 2019 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	51,991	$22.28	$1,158,354.28	Disclosure SEC source: 0001209191-19-042001 · doc4.xml · nonDerivative · entry 3 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67 to $22.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
July 11, 2019 Filed Jul 13, 2019 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	28,847	$2.19	$63,174.93	Disclosure SEC source: 0001209191-19-042001 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 51,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 11, 2019 Filed Jul 13, 2019 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	23,144	$2.50	$57,860.00	Disclosure SEC source: 0001209191-19-042001 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 23,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 08, 2019 Filed Jul 10, 2019 17:08 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	700	$43.42	$30,394.00	Disclosure SEC source: 0001209191-19-041709 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.26 to $43.545, inclusive. Read SEC document
July 08, 2019 Filed Jul 10, 2019 17:08 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	12,415	$42.85	$531,982.75	Disclosure SEC source: 0001209191-19-041709 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,999 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.195 to $43.19, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · balance_after: Includes 183 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019. Read SEC document
June 13, 2019 Filed Jun 17, 2019 18:54 UTC	CHIASMA, INC CHMA · Entity 136487	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $7.98	$0.00	Disclosure SEC source: 0001209191-19-037507 · doc4.xml · derivative · entry 1 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (1) June 13, 2020 and (ii) the date of the issuer's next annual meeting of the stockholders. Read SEC document
June 11, 2019 Filed Jun 13, 2019 17:16 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $5.49	$0.00	Disclosure SEC source: 0001209191-19-036854 · doc4.xml · derivative · entry 6 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,856 Underlying: Common Stock · 9,000 shares Expires 2020-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document
June 11, 2019 Filed Jun 13, 2019 17:16 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.61	$0.00	Disclosure SEC source: 0001209191-19-036854 · doc4.xml · derivative · entry 5 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 15,000 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months. Read SEC document
June 11, 2019 Filed Jun 13, 2019 17:16 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	9,000	$5.49	$49,410.00	Disclosure SEC source: 0001209191-19-036854 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 13, 2019 17:16 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	15,000	$1.61	$24,150.00	Disclosure SEC source: 0001209191-19-036854 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 05, 2019 Filed Jun 6, 2019 17:03 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	142,100	$0.00 Strike: $43.54	$0.00	Disclosure SEC source: 0001209191-19-035132 · doc4.xml · derivative · entry 5 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,100 Underlying: Common Stock · 142,100 shares Expires 2029-06-05 F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document
June 05, 2019 Filed Jun 6, 2019 17:03 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	23,700	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035132 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,231 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
June 04, 2019 Filed Jun 6, 2019 17:03 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	12,385	$42.91	$531,440.35	Disclosure SEC source: 0001209191-19-035132 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,531 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 233 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018. Read SEC document
May 29, 2019 Filed Jun 1, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	33,799	$0.00 Strike: $3.21	$0.00	Disclosure SEC source: 0001209191-19-033765 · doc4.xml · derivative · entry 3 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,799 shares Expires 2028-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 29, 2019 Filed Jun 1, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	33,799	$18.45	$623,534.09	Disclosure SEC source: 0001209191-19-033765 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
May 29, 2019 Filed Jun 1, 2019 00:02 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	33,799	$3.21	$108,494.79	Disclosure SEC source: 0001209191-19-033765 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
May 20, 2019 Filed May 22, 2019 00:14 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	7,428	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-031868 · doc4.xml · derivative · entry 5 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,428 Underlying: Ordinary Shares · 7,428 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F8 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year. F9 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 20, 2019 Filed May 22, 2019 00:14 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	9,658	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0001209191-19-031868 · doc4.xml · derivative · entry 4 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,658 Underlying: Ordinary Shares · 9,658 shares Expires 2029-05-20 F6 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 17, 2019 Filed May 22, 2019 00:14 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	13,174	$0.00 Strike: $3.21	$0.00	Disclosure SEC source: 0001209191-19-031868 · doc4.xml · derivative · entry 3 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,799 Underlying: Ordinary Shares · 13,174 shares Expires 2028-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 17, 2019 Filed May 22, 2019 00:14 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	13,174	$18.00	$237,138.59	Disclosure SEC source: 0001209191-19-031868 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
May 17, 2019 Filed May 22, 2019 00:14 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	13,174	$3.21	$42,288.54	Disclosure SEC source: 0001209191-19-031868 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	11,572	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 14 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 11,572 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	28,500	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 13 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 28,500 shares Expires 2024-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	13,500	$0.00 Strike: $5.58	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 12 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 13,500 shares Expires 2023-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $9.34	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 11 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 Underlying: Ordinary Shares · 45,000 shares Expires 2022-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	21,146	$0.00 Strike: $3.06	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 10 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,146 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	5,786	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · derivative · entry 9 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,572 Underlying: Ordinary Shares · 5,786 shares Expires 2025-07-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	98,572	$18.00	$1,774,296.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 8 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	11,572	$2.50	$28,930.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 7 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 98,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	28,500	$1.87	$53,295.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 6 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 87,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	13,500	$5.58	$75,330.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 5 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 58,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	45,000	$9.34	$420,300.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 4 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By David M. Stack Family Trust Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	26,932	$18.00	$484,776.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 3 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	21,146	$3.06	$64,706.76	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 10, 2019 Filed Jan 12, 2019 01:18 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	5,786	$2.50	$14,465.00	Disclosure SEC source: 0001209191-19-003499 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 18, 2018 Filed Dec 20, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $5.49	$0.00	Disclosure SEC source: 0001209191-18-063670 · doc4.xml · derivative · entry 6 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,856 Underlying: Common Stock · 6,000 shares Expires 2020-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document
December 18, 2018 Filed Dec 20, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	6,000	$0.00 Strike: $1.61	$0.00	Disclosure SEC source: 0001209191-18-063670 · doc4.xml · derivative · entry 5 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 6,000 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months. Read SEC document
December 18, 2018 Filed Dec 20, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	6,000	$5.49	$32,940.00	Disclosure SEC source: 0001209191-18-063670 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 18, 2018 Filed Dec 20, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionCommon Stock	6,000	$1.61	$9,660.00	Disclosure SEC source: 0001209191-18-063670 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2018 Filed Nov 19, 2018 16:06 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	4,558	$47.70	$217,416.60	Disclosure SEC source: 0001209191-18-059156 · doc4.xml · nonDerivative · entry 2 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,683 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.57 to $47.975, inclusive. Read SEC document
November 15, 2018 Filed Nov 19, 2018 16:06 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	10,442	$47.25	$493,384.50	Disclosure SEC source: 0001209191-18-059156 · doc4.xml · nonDerivative · entry 1 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,241 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.57 to $47.56, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document
October 11, 2018 Filed Oct 15, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $5.49	$0.00	Disclosure SEC source: 0001209191-18-054974 · doc4.xml · derivative · entry 8 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,856 Underlying: Common Stock · 15,000 shares Expires 2020-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the option shares on December 29, 2011 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document
October 11, 2018 Filed Oct 15, 2018 16:30 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	Exercise / conversionStock Option (Right to Buy) · Derivative	18,190	$0.00 Strike: $1.61	$0.00	Disclosure SEC source: 0001209191-18-054974 · doc4.xml · derivative · entry 7 STACK DAVID M · CIK 0001204788 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 18,190 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested as to 50% of the option shares on February 2, 2011, 19,377 option shares vested on February 3, 2011, and the remaining option shares vested in successive equal monthly installments for the subsequent 19 months. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.